StockData

Axogen vs Sanara MedTech

AXGN and SMTI side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AXGN and SMTI compare

Axogen is the larger company, worth 11 times as much as Sanara MedTech ($3.3B against $301M).

Axogen grew revenue faster over the last twelve months (24.3% versus 13.0% for Sanara MedTech).

Axogen keeps more of each dollar of sales as profit, with a net margin of −12.0% compared with −29.2% at Sanara MedTech.

Axogen scores higher on the StockData Score (11 against 6 for Sanara MedTech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAXGNSMTI
Size and price
Market cap$3.3B$301M
Share price$55.37$32.73
Change, 1 year135%51.9%
Change, 5 years477%14.2%
Beta (5Y)1.321.43
Employees622108
StockData Score
Total score11 (better)6
Valuation score00
Growth score33
Performance score3 (better)1
Health score5 (better)2
Dividend score00
Valuation
P/S12.4×2.7× (better)
P/B6.7× (better)37.9×
EV/EBITDA–30.4×
P/FCF150×66.8× (better)
FCF yield0.67%1.5% (better)
Fair value$22.90$13.42
Margin of safety−142% (better)−144%
Growth
Revenue growth (TTM)24.3% (better)13.0%
Revenue growth, 5Y average14.9%45.9% (better)
Profitability
Gross margin74.2%93.0% (better)
Operating margin−5.2%7.7% (better)
Net margin−12.0% (better)−29.2%
FCF margin8.3% (better)4.1%
Return on equity−10.3% (better)−148%
Return on invested capital−7.9%13.1% (better)
Financial health
Debt / equity0.005.85 (better)
Net debt / EBITDA–2.85
Interest coverage−5.7×1.2× (better)
Current ratio12.02 (better)2.58
Altman Z-score37.04 (better)3.76
Piotroski F-score5 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions90.4%19.4%
Held by insiders7.6%14.9%
Insider net buying, 12 months−$17.1M–
Short interest, % of float12.7%5.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.